HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Recordati SpA

‘Is This Doomsday Concern, Or Is It Reality?’ Verily CMO On AI’s Future, Lightpath Metabolic, More

Andrew Trister, Verily’s chief medical and scientific officer, discusses Verily’s newly launched Lightpath Metabolic solution, featuring GLP-1 prescription, AI and strengthened clinical support. Plus, the Google health tech spinout's plans for the Study Watch, the Alzheimer’s research landscape, and AI development and regulation in a new era of uncertainty.

Digital Health Artificial Intelligence

‘Is This Doomsday Concern, Or Is It Reality?’ Verily CMO On AI’s Future, Lightpath Metabolic, More

Andrew Trister, Verily’s chief medical and scientific officer, spoke with Medtech Insight at the HLTH Europe conference about Verily’s newly launched Lightpath Metabolic solution, featuring GLP-1 prescription, AI and strengthened clinical support. Trister also talked about plans for the Study Watch and offered views on the Alzheimer’s research landscape and AI development and regulation in a new era of uncertainty.

HLTH Artificial Intelligence

Rapport Navigates Rough IPO Market With Well-Received Offering

Rapport Therapeutics launched an initial public offering in the middle of a proposed price range, and the CNS-focused company closed slightly above its IPO price on its first day of trading.

Financing Business Strategies

Otsuka Pays Price As AVP-786 Dropped For Alzheimer's Agitation

Otsuka has now formally decided to terminate the development of AVP-786 for Alzheimer's agitation, for which it is set to book another JPY100bn loss this year, and marking a major setback for an asset that was a key attraction in a previous large acquisition.

Research & Development Neurology
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Bouchara Recordati
    • Dr. F. Frik Ilaç A.S.
    • Opalia Pharma S.A.
    • Orphan Europe
    • Recordati Pharmaceuticals Ltd.
    • Laboratorios Casen Fleet
    • Italchimici S.p.A.
    • Pro Farma AG
    • Recordati S.A. Chemical and Pharmaceutical Company
    • Recordati Rare Diseases Canada Inc.
    • Natural Point S.r.l.
    • Tonipharm S.A.S.
    • FIMEI S.p.A
    • Rossini Investimenti S.p.A
UsernamePublicRestriction

Register